Отзывы сотрудников о компании MDCE（苏州希毅医学研究有限公司）

• General 

SUZHOU MDCE CO., LTD (MDCE) was established on May 7,2021 with a registered capital of 1 million CNY (≈11 million RUB), preparing to become a listed company in 3 to 5 years. MDCE is located in Zhongxin building, Suzhou City, Jiangsu province, China, which is a global consulting company providing comprehensive and flexible solutions for Chinese medicine entering the international market. Relying on our rich experience in overseas clinical research and the support of global clinical strategies, MDCE customized an efficient and accurate sea going plan for enterprises, which can reduce risks, shorten the cycle, save funds, and accelerate the expansion of overseas markets.

• Enterprise positioning

MDCE is a global consulting firm that provides comprehensive and flexible solutions for Chinese pharmaceutical companies wishing to list their products overseas.

• Enterprise business

Relying on rich overseas clinical research experience and global clinical strategy support, MDCE customizes efficient and accurate overseas programs for companies to reduce risk, shorten cycles, save capital, and accelerate overseas market expansion.

• Cooperative partner

At present, MDCE has established cooperation with more than 60 well-known organizations & Medical institutions in the world, including WHO, Harvard University, National Cancer Center of Singapore (NCCS), South African Medical Research Council Vaccine and Infectious Disease Analysis and Research Department (Wits-VIDA), Malaysian Ministry of Health, Malian Drug Administration, Rwanda Drug Authority, University Hospital of Geneva, etc.

• Enterprise achievement

Now MDCE has served more than 30 enterprises, including domestic pharmaceutical companies & innovative medical device companies, and helped its clients realize 14 billion yuan in profit growth and more than 30 billion yuan in market value increase.

• Team Members

MDCE’s team members are drawn from the world's top pharmaceutical companies or top international universities. They have long been involved in planning and strategy for global multi-regional clinical trials and have extensive experience in overseas clinical strategy, clinical studies and registration.